25 May 2013
Keywords: promising, ph, i/ii, nhl, efficacy, pixantrone, cell
Article | 08 June 2009
Cell Therapeutics says that a review of early- and mid-stage data on its cancer drug candidate pixantrone suggests it is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
24 May 2013
© 2013 thepharmaletter.com